Renaissance and GlaxoSmithKline Transfer Nine Products
06/05/2013
Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK.
The products from GSK and Stiefel, which will be marketed through Renaissance's branded division Prestium Pharma, include:
1. Evoclin® (clindamycin phosphate) Foam, 1%
2. Extina® (ketoconazole) Foam, 2%
3. Luxiq® (betamethasone valerate) Foam, 0.12%
4. Olux® (clobetasol propionate) Foam, 0.05%
5. Olux-E® (clobetasol propionate) Foam, 0.05%
6. Vusion® (miconazole nitrate 0.25%, zinc oxide 15% and white petrolatum 81.35%) Ointment
7. Zovirax® (acyclovir) Capsules
8. Zovirax® (acyclovir) Tablets
9. Zovirax® (acyclovir) Suspension